Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

122.40USD
27 Feb 2017
Change (% chg)

$-0.33 (-0.27%)
Prev Close
$122.73
Open
$122.13
Day's High
$122.88
Day's Low
$122.13
Volume
1,772,925
Avg. Vol
2,389,608
52-wk High
$126.07
52-wk Low
$105.05

Latest Key Developments (Source: Significant Developments)

Jupiter says J&J purchase of Actelion "very good outcome"
Thursday, 26 Jan 2017 06:00am EST 

: Jupiter Fund Manager Mike Buhl-nielsen: Johnson & Johnson purchase of actelion is "very good outcome", says can see "clear synergies for j&j" . Buhl-Nielsen holds Actelion shares Further company coverage: [JNJ.N] [ATLN.S] ((carolyn.cohn@thomsonreuters.com;)).  Full Article

Pacira Pharmaceuticals collaborates with Depuy Synthes to support promotion, education and training of exparel in orthopedics
Wednesday, 25 Jan 2017 07:30am EST 

Pacira Pharmaceuticals Inc : Pacira Pharmaceuticals announces collaboration with Depuy Synthes to support promotion, education and training of Exparel in orthopedics .Pacira Pharmaceuticals - initiation of agreement with Depuy Synthes sales to market and promote use of exparel for orthopedic procedures in U.S. market.  Full Article

J&J sees 2017 effective tax rate 19-20 percent
Tuesday, 24 Jan 2017 10:07am EST 

Johnson & Johnson : Johnson & Johnson ceo says no definitive timeline for review of diabetes care businesses . J&J CEO says planning expanded disclosures on drug pricing and research and development expenses . J&J says expects to launch 10 new products by 2019 with $1 billion sales potential . J&J CFO says plans to complete ongoing share repurchase program in 1H 2017 .J&J sees 2017 effective tax rate 19-20 percent.  Full Article

Ethicon Endo-Surgery announces acquisition of Megadyne Medical Products
Friday, 20 Jan 2017 08:30am EST 

Ethicon Endo-Surgery Inc: Ethicon Endo-Surgery says financial terms of transaction have not been disclosed .Ethicon announces acquisition of Megadyne Medical Products, Inc..  Full Article

Johnson & Johnson reports 7.4 pct stake in Merus NV as of Dec 31, 2016
Wednesday, 18 Jan 2017 05:59pm EST 

Johnson & Johnson :Johnson & Johnson reports 7.4 percent passive stake in Merus NV as of Dec 31, 2016 - SEC filing.  Full Article

Orthocell announces collaboration with Johnson & Johnson
Wednesday, 11 Jan 2017 07:21pm EST 

Orthocell Ltd : Orthocell announces collaboration with Johnson & Johnson Innovation . Announced a research collaboration agreement with Depuy Synthes Products, Inc., part of Johnson & Johnson family of companies .Deal for for its ortho-ati® stem cell approach for regeneration of degenerate tendons and ligaments.  Full Article

Orthocell announces collaboration with Johnson & Johnson
Wednesday, 11 Jan 2017 05:58pm EST 

Orthocell Ltd : Orthocell announces collaboration with Johnson & Johnson Innovation . Announced a research collaboration agreement with Depuy Synthes Products, Inc., part of Johnson & Johnson family of companies .Deal for for its ortho-ati® stem cell approach for regeneration of degenerate tendons and ligaments.  Full Article

Bird Rock Bio receives approval to start first in human clinical trial for Namacizumab, enters into agreement with GE Healthcare for process development and scale-up to provide clinical phase 2
Wednesday, 11 Jan 2017 08:00am EST 

General Electric Co : Bird Rock Bio receives approval to start first in human clinical trial for Namacizumab, enters into agreement with GE Healthcare for process development and scale-up to provide clinical phase 2 cGMP material, and enters into a collaboration and option agreement with Janssen Pharmaceuticals Inc . Bird Rock Bio says has received approval for initiation of a two-part phase 1 clinical trial for Namacizumab . Bird Rock Bio says entered into agreement with GE Healthcare for process development, formulation, manufacture of Namacizumab in preparation for phase 2 studies . Bird Rock Bio says phase 1 trial, process development, phase 2 preparation to be funded under collaboration, option agreement with Janssen Pharmaceuticals .Bird Rock Bio says entered collaboration, option agreement, under which Janssen Pharmaceuticals has exclusive right to acquire co after phase 1 data readout.  Full Article

Johnson & Johnson announces quarterly dividend for Q1 2017
Tuesday, 3 Jan 2017 06:40am EST 

J&J : Johnson & Johnson announces quarterly dividend for first quarter 2017 .Sets quarterly cash dividend of $0.80per share.  Full Article

Ionis Pharmaceuticals says earned $5 mln milestone payment from Janssen Biotech
Thursday, 22 Dec 2016 07:00am EST 

Ionis Pharmaceuticals Inc : Ionis Pharmaceuticals earns milestone payment from Janssen for advancing a new program under GI collaboration . Ionis Pharmaceuticals - earned $5 million milestone payment from Janssen Biotech associated with validation of undisclosed target to treat patients with gastrointestinal autoimmune disease . Ionis Pharmaceuticals - under collaboration, Ionis,Janssen will continue to evaluate target with goal of advancing an antisense drug into development . Ionis Pharma -under terms of agreement, co is eligible to receive nearly $800 million in development, regulatory, sales milestone payments, license fees .Ionis Pharmaceuticals Inc - will receive tiered royalties that on average are double-digits on sales from any product that is commercialized.  Full Article

More From Around the Web

BRIEF-Johnson & Johnson says received a subpoena in Feb. from the U.S. attorney's office for the District of Massachusetts

* j&j - in february 2017, johnson & johnson received a subpoena from the united states attorney's office for the district of massachusetts